EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus

Xu Li, Xinmeng Zhang, Xueyuan Xie, Taimin Dong, Chengxu Lv, Ranran Guan, Wenyue Zhang, Guoxia Ji, Fanghui Chen, Shiben Wang, Xuekun Wang iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252111476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Xu Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Macromolecular Drug Development and Manufacturing, School of Pharmaceutical Sciences and Food Engineering, Liaocheng Unive…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Receptors, G-Protein-Coupled, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Youth Innovation Team Plan" of Shandong Province Higher Education, Major Project of Research and Development of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus (DM) is a common metabolic disease that poses a severe threat to human health. Despite a range of therapeutic approaches, there remains a lack of effective and safe therapies with the existing drugs. Therefore, there is an urgent need to develop novel, effective, and safe therapeutic strategies for DM. Free fatty acid receptor 4 (FFAR4), also known as GPR120, is a member of the G protein-coupled receptor family, which has received considerable attention as an attractive new therapeutic target for treating DM. In the present study, based on the structure of TUG-891, which has excellent activity and selectivity, a series of novel FFAR4 agonists was designed by replacing the phenylpropanoic acid β position carbon atom with an oxygen atom, while replacing the linking oxymethylene with an amide-linking group. The target compounds were evaluated for FFAR4 agonistic activity, and the preferred compounds were evaluated for selectivity, oral glucose tolerance in normal ICR mice, antidiabetic activity in diet-induced obese (DIO) mice, pharmacokinetic properties in ICR mice and molecular modeling studies. The results showed that compound 10f possessed excellent FFAR4 agonistic activity and selectivity, significantly improved glucose tolerance in normal ICR mice, lowered blood glucose and promoted insulin secretion in a dose-dependent manner in DIO mice, and showed favorable pharmacokinetic properties. These results indicate that compound 10f may be a promising compound that deserves further structure–activity relationship and pharmacological studies for the development of antidiabetic drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Receptors, G-Protein-CoupledHypoglycemic AgentsAnimalsMiceHumansMaleMice, Inbred ICRMolecular Docking SimulationDiabetes Mellitus, ExperimentalStructure-Activity Relationship

Stichwörter der Autor:innen

designevaluationfree fatty acid receptor 4 agonistssynthesistype 2 diabetes mellitus

Substanzen

Receptors, G-Protein-CoupledHypoglycemic AgentsFFAR4 protein, mouseFFAR4 protein, human

Autor:innen und Institutionen

  • National Key Laboratory of Macromolecular Drug Development and Manufacturing, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, 1 Hunan Street, Liaocheng 252059, China.
  • School of Chemistry and Chemical Engineering, Liaocheng University, 1 Hunan Street, Liaocheng 252059, China.

ORCID-Profile: Xuekun Wang

Förderung

  • National Natural Science Foundation of China
  • Youth Innovation Team Plan" of Shandong Province Higher Education
  • Major Project of Research and Development of Shandong Province
  • Guangyue Young Scholar Innovation Team of Liaocheng University
  • Doctoral Foundation of Liaocheng University
  • Youth Innovation Team Plan” of Shandong Province Higher Education

Zitieren

APA

Li, X., Zhang, X., Xie, X., Dong, T., Lv, C., Guan, R., Zhang, W., Ji, G., Chen, F., Wang, S., & Wang, X. (2024). Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111476

Vancouver

Li X, Zhang X, Xie X, Dong T, Lv C, Guan R, et al. Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111476

BibTeX
@article{Li2024,
  author = {Li, Xu and Zhang, Xinmeng and Xie, Xueyuan and Dong, Taimin and Lv, Chengxu and Guan, Ranran and Zhang, Wenyue and Ji, Guoxia and Chen, Fanghui and Wang, Shiben and Wang, Xuekun},
  title = {Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252111476}
}
Kostenlos starten →